AbbVie Inc. ABBV
AbbVie Inc. (NYSE: ABBV) is an immunology/inflammation drug developer. Its lead program, Skyrizi, is marketed for Multiple immunology indications (plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis). Its next catalyst on record is Skyrizi: CD subcutaneous induction regulatory review (EU application submitted Aug 2026, US approval Oct 2026) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Skyrizi — CD subcutaneous induction regulatory review (EU application submitted Aug 2026, US approval Oct 2026) (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Skyrizi | Multiple immunology indications | antibody | Approved |
| Rinvoq | Multiple immunology indications (RA, UC, AD, pJIA, vitiligo, alopecia areata) | small molecule | Approved |
| Humira | Multiple immunology indications | antibody | Approved |
| Vraylar | Bipolar/psychiatric disorders | small molecule | Approved |
| Botox Therapeutic | Multiple neurology indications | biologic-other | Approved |
| Ubrelvy | Acute migraine | small molecule | Approved |
| Qulipta | Migraine prevention/acute treatment | small molecule | Approved |
| Juvmo (tavapadon) | Parkinson's disease | small molecule | Approved |
| Vyalev | Parkinson's disease | device-combination | Approved |
| Venclexta | CLL/AML | small molecule | Approved |
| Imbruvica | CLL and other B-cell malignancies | small molecule | Approved |
| Elahere | Ovarian cancer | antibody | Approved |
Recent results and decisions
- Oct 30, 2026approval FDA approved Skyrizi for subcutaneous induction in moderately to severely active Crohn's disease.
The U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab) for subcutaneous (SC) induction in the treatment of moderately to severely active Crohn's disease (CD).
Filing - Oct 30, 2026submitted AbbVie submitted an application to the EMA for Skyrizi for subcutaneous induction in Crohn's disease.
AbbVie announced it submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi for SC induction in the treatment of adult patients with moderately to severely active CD.
Filing - Oct 30, 2026met Lutikizumab met the primary endpoint and majority of secondary endpoints in Phase 3 INTREPID study for hidradenitis suppurativa.
In the study, lutikizumab met the primary endpoint, achieving a significantly higher response rate of Hidradenitis Suppurativa Clinical Response 75 (HiSCR 75) at Week 16 compared with placebo.
Filing
12 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved immunology/inflammation companies
- Alvotech ALVO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.